BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioMarin Pharmaceutical Inc. ( BMRN ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Day 2 of our London Healthcare Conference. Great to see everyone.

Seeking Alpha • Nov 18, 2025

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

SAN RAFAEL, Calif. , Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.

PRNewsWire • Nov 11, 2025

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet alone FDA PDUFA target action date of Feb. 28, 2026 SAN RAFAEL, Calif. , Oct. 29, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company's PALYNZIQ ® (pegvaliase-pqpz) supplemental Biologics License Application (sBLA) to expand treatment to include adolescents aged 12-17 with phenylketonuria (PKU).

PRNewsWire • Oct 29, 2025

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.

Benzinga • Oct 28, 2025

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday

The biotech published its latest set of quarterly results. It posted a surprise net profit for the period.

The Motley Fool • Oct 28, 2025

BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy

BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.

Zacks Investment Research • Oct 28, 2025

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

BioMarin Pharmaceuticals shares have fallen to decade lows, reflecting investor concerns despite profitable growth and a strong net cash position. Its results showed double-digit revenue growth, but recent quarters revealed slowing sales momentum, especially for key drugs like Voxzogo and Roctavian. Competition and product setbacks cast doubt on achieving 2027 growth targets, even as the company maintains a sub-3x sales multiple and robust cash reserves.

Seeking Alpha • Oct 28, 2025

Biomarin Up After Q3 Earnings: Here's Everything You Need to Know

BioMarin Pharmaceutical (Nasdaq: BMRN) missed both revenue and earnings estimates in the third quarter, and yet, shares are up 1% in after-hours trading.

24/7 Wall Street • Oct 27, 2025

BioMarin Pharma plans to divest struggling gene therapy

BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.

Reuters • Oct 27, 2025

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2025 Earnings Call October 27, 2025 4:30 PM EDT Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Julian Pino Christopher Raymond - Raymond James & Associates, Inc., Research Division Sean Laaman - Morgan Stanley, Research Division Presentation Operator Hello, and welcome to the BioMarin Pharmaceutical Third Quarter 2025 Conference Call. [Operator Instructions].

Seeking Alpha • Oct 28, 2025